Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.6050 (5.33%) ($7.0450 - $7.6050) on Mon. Sep. 12, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.77% (three month average) | RSI | 59 | Latest Price | $7.6050(5.33%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.4% a day on average for past five trading days. | Weekly Trend | TGTX declines -1.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) HYG(95%) ONLN(96%) LQD(95%) IWC(94%) JNK(87%) | Factors Impacting TGTX price | TGTX will decline at least -3.385% in a week (0% probabilities). XRT(268%) ARKG(87%) XLRE(50%) UUP(-81%) USO(-29%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.385% (StdDev 6.77%) | Hourly BBV | 1.7 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-8.05(-205.85%) | 5 Day Moving Average | $6.86(10.86%) | 10 Day Moving Average | $6.91(10.06%) | 20 Day Moving Average | $7.1(7.11%) | To recent high | -9.7% | To recent low | 103.6% | Market Cap | $963m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |